吡贝地尔治疗注意缺陷多动障碍的临床效果分析  

Clinical effect of attention deficit and hyperactive disorder in the treatment of hyperactivity in children

作　　者：张素珍 ZHANG Suzhen(Department of Pediatrics,Chengwu County People’s Hospital,Heze,Shandong 274200,China)

机构地区：[1]成武县人民医院儿科,山东菏泽274200

出　　处：《医药前沿》2023年第6期37-39,共3页Journal of Frontiers of Medicine

摘　　要：目的:分析多巴胺受体激动剂治疗注意缺陷多动障碍的临床效果。方法:选取成武县人民医院2020年9月—2022年10月成武县人民医院收治的注意缺陷多动障碍患儿82例,按随机数字表法分为对照组与观察组各41例。对照组口服盐酸哌甲酯缓释片治疗,观察组予以吡贝地尔缓释片治疗,均持续治疗1个月。比较两组临床疗效、儿童行为状况、多巴胺水平、不良反应。结果:观察组总有效率(95.12%)高于对照组(78.05%),差异有统计学意义(P<0.05);治疗前,两组儿童行为状况、多巴胺水平比较,差异无统计学意义(P>0.05);治疗后,观察组Conners标准儿童行为评定量表(PSQ)中学习问题评分(1.40±0.33)分、品行行为评分(1.46±0.20)分、心身问题评分(0.80±0.11)分、焦虑行为评分(1.32±0.21)分、冲动-多动评分(1.52±0.20)分、多动指数评分(1.37±0.21)分均低于对照组,多巴胺水平(695.43±38.54)μg/mL高于对照组,差异有统计学意义(P<0.05);观察组不良反应总发生率(4.88%)低于对照组,差异有统计学意义(P<0.05)。结论:多巴胺受体激动剂治疗注意缺陷多动障碍能够有效减轻多动症状,提高多巴胺水平,且安全性高,值得临床应用。Objective To analyse the clinical effect of dopamine receptor agonists in the treatment of children with attention deficit and hyperactive disorder(ADHD).Methods 82 children with ADHD admitted to Chengwu County People’s Hospital from September 2020 to October 2022 were divided into two groups according to random number table method,41 cases in each group.The control group was treated with oral sustained-release tablets of methylphenidate hydrochloride,and the observation group was treated with sustained-release tablets of pirbedil,both of which lasted for 1 month.The clinical efficacy,children’s behavior,dopamine level and adverse reactions were compared between the two groups.Results Compared with the control group(78.05%),the total effective rate of treatment in the observation group(95.12%)was higher(P<0.05);There was no significant difference between the two groups in children’s behavior and dopamine levels before treatment(P>0.05);After treatment,the scores of learning problems(1.40±0.33),conduct behavior(1.46±0.20),psychosomatic problems(0.80±0.11),anxiety behavior(1.32±0.21),impulse-hyperactivity(1.52±0.20)and hyperactivity index(1.37±0.21)in the Conners Standard Children’s Behavior Rating Scale(PSQ)in the observation group were lower than those in the control group,and the level of dopamine(695.43±38.54)μg/mL was higher than that of the control group(P<0.05);Compared with the control group(19.51%),the incidence of adverse reactions in the observation group(4.88%)was lower(P<0.05).Conclusion Dopamine receptor agonist can effectively relieve hyperactivity symptoms and increase dopamine level in children with ADHD,and it is safe.

关 键 词：注意缺陷多动障碍 盐酸哌甲酯缓释片 吡贝地尔缓释片 儿童行为状况 多巴胺 不良反应 

分 类 号：R593.28[医药卫生—内科学]